Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Net Cash Flow of $10.6 million for Q1 2026, down 88.82% year-over-year from $94.4 million in Q1 2025, and down 87.5% quarter-over-quarter from $84.5 million in Q4 2025.
Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026) Analysis & Trends
Oculis Holding AG's Net Cash Flow history runs 5 years deep, the most recent figure standing at $10.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 88.82% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $56.0 million (down 40.7% YoY), while the FY2025 annual figure was $72.0 million, up 674.33% from the prior year.
- Net Cash Flow for Q1 2026 stood at $10.6 million, down from $84.5 million in the prior quarter.
- The five-year high for Net Cash Flow was $94.4 million in Q1 2025, with the low at -$20.1 million in Q2 2025.
- The 5-year median for Net Cash Flow is -$5.7 million (2022), against an average of $14.7 million.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow tumbled 205.76% in 2023, then jumped 1030.89% in 2025.
- Oculis Holding AG's Net Cash Flow stood at -$8.6 million in 2022, then surged by 219.38% to $10.3 million in 2023, then sank by 187.95% to -$9.1 million in 2024, then soared by 1030.89% to $84.5 million in 2025, then slumped by 87.5% to $10.6 million in 2026.
- Business Quant data shows OCS's Net Cash Flow at $10.6 million in Q1 2026, $84.5 million in Q4 2025, and -$18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 6.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.07 Mn |
| Jun 30, 2026 | 6.07 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 84.47 Mn |
| Dec 31, 2025 | 84.47 Mn |
| Sep 30, 2025 | -18.91 Mn |
| Sep 30, 2025 | -18.91 Mn |
| Jun 30, 2025 | -20.10 Mn |
| Jun 30, 2025 | -20.10 Mn |
| Mar 31, 2025 | 94.39 Mn |
| Mar 31, 2025 | 94.39 Mn |
| Dec 31, 2024 | -9.07 Mn |
| Dec 31, 2024 | -9.07 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Jun 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 22.47 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |